Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: pazopanib (GW786034) 400 mg|DRUG: lapatinib (GW572016) 1500 mg|DRUG: lapatinib (GW572016) 1000 mg|DRUG: pazopanib (GW786034) 800 mg
Sponsor: GlaxoSmithKline